Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ribociclib + Spartalizumab in Advanced Breast and Ovarian Cancer
NCT03294694Phase 1Terminated
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Nov 2017
- Primary completion
- Oct 2020
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label trial of spartalizumab in Hormone-Receptor-Positive Breast Cancer and Epithelial Ovarian Cancer (EOC), sponsored by Dana-Farber Cancer Institute. Primary endpoint: Maximum Tolerated Dose / Recommended Phase 2 Dose at 4 weeks. Started Nov 2017; status: terminated.
02
Drugs
spartalizumab
03
Conditions
Hormone-Receptor-Positive Breast CancerEpithelial Ovarian Cancer (EOC)
Beyond the preview
Go deeper on NCT03294694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03294694.